These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 35236741)
1. Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy. Hu J; He J; Wang Y; Zhao Y; Fang K; Dong Y; Chen Y; Zhang Y; Zhang C; Wang H; Tan J; Wang J; Zi R; Liu C; Liang H; Guo Y; Ou J J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236741 [TBL] [Abstract][Full Text] [Related]
2. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
3. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667 [TBL] [Abstract][Full Text] [Related]
5. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Zhang X; Niedermann G Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901 [TBL] [Abstract][Full Text] [Related]
6. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810 [No Abstract] [Full Text] [Related]
8. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy. Sun L; Ma Z; Zhao X; Tan X; Tu Y; Wang J; Chen L; Chen Z; Chen G; Lan P J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272565 [TBL] [Abstract][Full Text] [Related]
9. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model. Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233 [TBL] [Abstract][Full Text] [Related]
10. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice. Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956 [TBL] [Abstract][Full Text] [Related]
11. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8 Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542 [No Abstract] [Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
14. TOX promotes the exhaustion of antitumor CD8 Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813 [TBL] [Abstract][Full Text] [Related]
15. Combinatorial immunotherapy induces tumor-infiltrating CD8 Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555 [TBL] [Abstract][Full Text] [Related]
17. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380 [TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575 [TBL] [Abstract][Full Text] [Related]
20. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]